rolitetracycline and ebselen

rolitetracycline has been researched along with ebselen* in 1 studies

Other Studies

1 other study(ies) available for rolitetracycline and ebselen

ArticleYear
Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
    European journal of medicinal chemistry, 2019, Oct-01, Volume: 179

    Insulin-degrading enzyme, IDE, is a metalloprotease implicated in the metabolism of key peptides such as insulin, glucagon, β-amyloid peptide. Recent studies have pointed out its broader role in the cell physiology. In order to identify new drug-like inhibitors of IDE with optimal pharmacokinetic properties to probe its multiple roles, we ran a high-throughput drug repurposing screening. Ebselen, cefmetazole and rabeprazole were identified as reversible inhibitors of IDE. Ebselen is the most potent inhibitor (IC

    Topics: Azoles; Biocatalysis; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Repositioning; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Insulysin; Isoindoles; Molecular Structure; Organoselenium Compounds; Structure-Activity Relationship

2019